OncLive - Bringing the Oncology Community Together

Home

Nurses

Urology

Targeted Therapies

Interactive

Meetings

OncLive TV

Blogs

Hennessy's Highlights

Publications

Oncology Conference Multimedia

Photos From the 2011 San Antonio Breast Cancer Symposium

Key Presentations and Meeting Takeaway Points From SABCS

Dr. Baselga Discusses the CLEOPATRA Pertuzumab Trial

Oncology Conference Articles

Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival

A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.

Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.

Dual Therapy With Pertuzumab Slows Advanced Breast Cancer

The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.

Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.

Obese Patients With HER2-Positive Breast Cancer Have Worse Outcomes but Trastuzumab Equalizes Weight Differences

A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.

The CLEOPATRA and BOLERO-2 Studies are Stirring Excitement at SABCS

The results of 2 studies likely to have a significant impact upon the treatment of women with metastatic breast cancer.

New Test Predicts Recurrence Risk in Patients With Ductal Carcinoma in Situ

A new 12-gene assay for predicting risk of recurrence for patients with ductal carcinoma in situ (DCIS).

Gene Signature Identifies Early Versus Late Versus No Recurrence in Hormone Receptor-Positive Breast Cancer

It may be possible to predict which women with HR+ invasive breast cancer will experience recurrence by using a series of gene expression profiles.

Oncology Publications